Skip to main content
Hansa Biopharma logo

Hansa Biopharma — Investor Relations & Filings

Ticker · HNSA ISIN · SE0002148817 LEI · 549300LLEO25ZJJ3NT91 ST Manufacturing
Open in API
Filings indexed 501 across all filing types
Latest filing 2018-11-01 Interim / Quarterly Rep…
Country SE Sweden
Listing ST HNSA

About Hansa Biopharma

https://www.hansabiopharma.com/

Hansa Biopharma is a commercial-stage biopharmaceutical company that develops and commercializes treatments for rare immunologic diseases. The company's core focus is its proprietary antibody-cleaving enzyme technology platform, designed to target and inactivate immunoglobulin G (IgG) antibodies. This approach aims to inhibit harmful IgG-mediated immune responses. Its lead product, imilfidase, is used to enable kidney transplantation in highly sensitized patients who have a low probability of finding a compatible donor. The company is also advancing its enzyme technology to address unmet medical needs in other therapeutic areas, including acute autoimmune diseases, gene therapy, and oncology, where IgG antibodies can be a barrier to treatment or a driver of the disease.

Recent filings

Filing Released Lang Actions
Interim / Quarterly Report 2018
Interim / Quarterly Report Classification · 100% confidence The document is a 'Delårsrapport' (Interim Report) for the period July–September 2018 for Hansa Medical. It contains comprehensive financial summaries, management commentary (Vd har ordet), operational overviews, and financial statements. It is not an announcement of a report, but the report itself, containing substantive financial data and analysis for a period shorter than a full fiscal year. 9M 2018
2018-11-01 Swedish
Ökning av antalet aktier och röster i Hansa Medical AB (publ)
Share Issue/Capital Change Classification · 98% confidence The document is a formal announcement from Hansa Medical AB dated October 25, 2018, detailing an increase in the registered share capital and the total number of outstanding shares and votes due to the issuance of C-shares (as part of an incentive program) and the exercise of stock options. This directly relates to changes in the company's capital structure and share count. Based on the definitions, the most appropriate category is 'Share Issue/Capital Change' (SHA), as it explicitly covers announcements regarding new share issues and capital structure changes. It is not a general earnings release (ER), a full annual report (10-K), or a simple dividend notice (DIV).
2018-10-31 Swedish
Increase of Number of Shares and Votes in Hansa Medical AB (publ)
Share Issue/Capital Change Classification · 98% confidence The document explicitly announces an 'Increase of Number of Shares and Votes' due to the issuance of class C shares and ordinary shares as part of an incentive program and warrant program completion. This directly relates to changes in the company's capital structure, specifically the number of outstanding shares. This aligns perfectly with the definition for 'Share Issue/Capital Change' (SHA). The document is a formal announcement detailing the resulting total number of shares and votes, not just a notice that a report is available (RPA/RNS).
2018-10-31 English
Kommuniké från extra bolagsstämma i Hansa Medical AB (publ)
AGM Information Classification · 99% confidence The document is titled 'Kommuniké från extra bolagsstämma i Hansa Medical AB (publ)' which translates to 'Communiqué from the Extraordinary General Meeting'. The content details decisions made at this meeting, specifically the approval of a board proposal regarding authorization for a new share issue (nyemission). This relates directly to capital structure changes and shareholder decisions made at a general meeting. Since the document explicitly details a decision regarding a share issue authorization, it falls under Capital/Financing Update (CAP) or potentially Share Issue/Capital Change (SHA). However, the context is the formal communication of decisions made at a general meeting concerning capital structure, which aligns closely with 'Capital/Financing Update' (CAP) as it discusses the authorization for future fundraising/share issuance. Given the focus on the authorization for a new share issue, CAP is the most precise fit over SHA (which is usually the announcement of the actual issue). It is not a DVA (Declaration of Voting Results) as it only states the decision was made, not the final tally of votes, nor is it an AGM-R (which is usually the presentation material). CAP is the best fit for a formal announcement of a capital-related resolution passed at a meeting.
2018-10-29 Swedish
Bulletin from the Extraordinary General Meeting of Hansa Medical AB
Share Issue/Capital Change Classification · 95% confidence The document explicitly details resolutions passed at an 'Extraordinary General Meeting' (EGM) concerning the authorization for the board to issue new shares. This action directly relates to changes in the company's capital structure and financing activities. While it occurs at a general meeting, the core subject is the authorization for share issuance, which aligns best with the 'Capital/Financing Update' (CAP) definition, or potentially 'Share Issue/Capital Change' (SHA). Since the resolution is about *authorizing* future issues up to a limit (10% of outstanding shares), it is fundamentally a capital structure decision. Given the options, 'CAP' (Capital/Financing Update) is a strong fit, as is 'SHA' (Share Issue/Capital Change). However, the text focuses on the *authorization* for future issues rather than an immediate issue announcement. Since the authorization directly impacts capital structure flexibility, I will classify it as CAP, as it is a financing/capital structure decision made at a meeting. It is not a standard AGM presentation (AGM-R) or a voting result announcement (DVA), but a specific resolution on capital.
2018-10-29 English
Presentation at ASN Kidney Week 2018 Highlights Stable Renal Function at up to 24 Months Following Transplantation Enabled by Imlifidase
Regulatory Filings Classification · 99% confidence The document is a press release from Hansa Medical AB dated October 26, 2018. It announces that data regarding their drug, imlifidase, was presented at the American Society of Nephrology (ASN) Kidney Week 2018 conference. The text includes quotes from the CEO and the presenting physician, summarizes the study results, and concludes with a statement that this information is obliged to be made public pursuant to the EU Market Abuse Regulation. This structure—announcing the presentation of clinical data and providing context—is characteristic of an Earnings Release (ER) or a general press release announcing significant business/clinical updates. Since it is not a full financial report (10-K or IR) or a transcript (CT), and it focuses on clinical data highlights rather than just financial performance, 'Earnings Release' (ER) is the most appropriate classification for a major clinical/business update announcement, even though it's not strictly quarterly earnings. Given the context of clinical data presentation, it functions as a key business update release.
2018-10-26 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.